歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > CytoskeletalSignaling > GDC-0068

瀏覽歷史

S80002

GDC-0068

源葉(MedMol) 98%
  • 英文名:
  • GDC-0068
  • 別名:
  • (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
  • CAS號:
  • 1001264-89-6
  • 分子式:
  • C24H32ClN5O2
  • 分子量:
  • 458
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S80002-1mg 98% ¥272.00元 9 - - - EA 加入購物車
源葉(MedMol) S80002-5mg 98% ¥544.00元 5 - - - EA 加入購物車
源葉(MedMol) S80002-10mg 98% ¥748.00元 6 - - - EA 加入購物車
源葉(MedMol) S80002-25mg 98% ¥1360.00元 4 - - - EA 加入購物車
源葉(MedMol) S80002-50mg 98% ¥2244.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S80002-100mg 98% ¥4216.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Ipatasertib (GDC-0068) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
  • 靶點: Akt1:5 nM (IC50);Akt2:18 nM (IC50);Akt3:8 nM (IC50);PKA:3100 nM (IC50);Akt
  • 體內(nèi)研究:
    Ipatasertib (GDC-0068) is typically efficacious in xenograft models in which Akt is activated because of genetic alterations including PTEN loss, PIK3CA mutations/amplifications, or HER2 overexpression. In these models, tumor growth delay, stasis, or regression is achieved at or below 100 mg/kg daily oral dose, which is the maximum dose tested in immunocompromised mice that is well tolerated. When tested in vivo, daily dosing of Ipatasertib (GDC-0068) in combination with RP-56976 induces tumor regression and stasis in the PC-3 and MCF7-neo/HER2 xenograft models, at doses where each single agent is ineffective or only causes modest tumor growth delay. Similarly, increased TGI is observed in the OVCAR3 ovarian cancer xenograft model when Ipatasertib (GDC-0068) is combined with NSC 241240. The combination of Ipatasertib (GDC-0068) with RP-56976 or NSC 241240 is tolerated with less than 5% body weight loss when compared with treatment with each chemotherapeutic agent alone
  • 參考文獻(xiàn):
    1. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27. 2. Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19(7):1760-72.
  • 溶解性: DMSO  :  220  mg/mL  (480.35  mM;  Need  ultrasonic)    H2O  :  3.57  mg/mL  (7.79  mM;  ultrasonic  and  warming  and  heat  to  60°C)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.183 ml 10.917 ml 21.834 ml
    5 mM 0.437 ml 2.183 ml 4.367 ml
    10 mM 0.218 ml 1.092 ml 2.183 ml
    50 mM 0.044 ml 0.218 ml 0.437 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。